A rotation back toward tech / growth stocks has taken longer then expected, but now showing some initial signs. If this eventuates, it should hopefully provide better a better backdrop for LBT.
Gary Glover of Novus Capital was on .******'s "The Call" Thursday (23rd June) and pointed out he liked Healthcare and Biotech which had been held back the past couple of years but could potentially lead here once the bear market is over.
Anyway, hopefully the business continues making good progress and Thermo Fisher is able to accelerate further sales in the US.
LBT Price at posting:
7.0¢ Sentiment: None Disclosure: Held
